Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To summarise, the peripheral neurological complications experienced by patients with primary
Sjögren's syndrome are particularly bothersome since they are common and often result in
significant disability related to pain or motor impairment. There is currently no standard
treatment for these patients.
As these neuropathies are caused by an immune system dysfunction, which is related to a
variety of different pathogenic mechanisms, the use of immunosuppressant or immunomodulator
drugs is often justified.
With the exception of the vascularitis-related multiplex mononeuropathies, other pSS-related
neuropathies could be suitable candidates for IV Ig treatment.